RESUMO
Haemophilia remains a complex disorder to diagnose and manage, requiring close cooperation between multidisciplinary healthcare professionals. There are still many unmet challenges in haemophilia care. The first Team Haemophilia Education (THE) meeting, held on 7-8 May 2015 in Amsterdam, The Netherlands, aimed to promote the optimal care of haemophilia patients through education of the multidisciplinary treatment team. This was achieved by reviewing the latest developments in haemophilia management, considering how these can be implemented in the clinic to improve patient care and providing a platform for networking and debate for all haemophilia treatment team members. Haemophilia treatment centres from several countries were asked to complete a premeeting online questionnaire to establish the biggest challenges that they face when managing patients. The concerns expressed were used to develop the agenda, which comprised a combination of formal presentations, case studies and informal workshops covering such topics as pharmacokinetics, laboratory assays and tailoring of treatment to individual patients. This report is a summary of the key developments in haemophilia care presented by various investigators and healthcare professionals at THE meeting 2015.
Assuntos
Hemofilia A/terapia , Hemofilia B/terapia , Atenção à Saúde , Gerenciamento Clínico , Educação Médica Continuada , Custos de Cuidados de Saúde , Hemofilia A/prevenção & controle , Hemofilia B/prevenção & controle , Humanos , Países Baixos , Equipe de Assistência ao Paciente , Pré-Medicação , Resultado do TratamentoRESUMO
INTRODUCTION: Work Package 4 Development of the standardisation criteria of the European Haemophilia Network project has the main objective of implementing a common and shared European strategy for a certification system for two levels of Haemophilia Centres: European Haemophilia Treatment Centres and European Haemophilia Comprehensive Care Centres in the Member States of the European Union. MATERIALS AND METHODS: An inclusive and participatory process for developing shared standards and criteria for the management of patients with inherited bleeding disorders has been carried out. The process has been implemented through four different consultation events involving the entire European community of stakeholders that significantly contributed in the drafting of the European Guidelines for the certification of Haemophilia Centres. RESULTS: The Guidelines set the standards for the designation of centres that provide specialised and multidisciplinary care (Haemophilia Comprehensive Care Centres) as well as local routine care (Haemophilia Treatment Centres). Standards cover several issues such as: general requirements; patient care; advisory services; laboratory; networking of clinical and specialised services. CONCLUSIONS: The drafting of the European Guidelines for the certification of Haemophilia Centres was performed adopting a rigorous methodological approach. In order to build the widest possible consensus to the quality standards, the main institutional and scientific stakeholders have been involved. The resulting document will significantly contribute in promoting standardisation in the quality of diagnosis and treatment in European Haemophilia Centres.
Assuntos
Certificação , Redes Comunitárias , Atenção à Saúde , Hemofilia A/terapia , Certificação/métodos , Certificação/organização & administração , Certificação/normas , Redes Comunitárias/organização & administração , Redes Comunitárias/normas , Atenção à Saúde/legislação & jurisprudência , Atenção à Saúde/métodos , Atenção à Saúde/normas , Europa (Continente) , Humanos , Guias de Prática Clínica como AssuntoRESUMO
The aim of this study was to assess the incremental cost effectiveness of on-demand versus prophylactic haemophilia therapy in Germany, Sweden, the United Kingdom and The Netherlands from the third-party payers' perspective. Using a decision tree model, the cost effectiveness of on-demand versus prophylactic therapy was analysed by extrapolating data from the European Haemophilia Economic Study to a 1-year analytic time horizon. Five hundred and six patients with severe haemophilia A and B, without inhibitors and at least 14 years of age, were enrolled in this study. Patients treated prophylactically had fewer bleeds than patients treated on-demand. With prophylactic treatment, the incremental cost per avoided bleeding ranged from 6,650 Euro dollars for patients 30 years of age or younger in Germany to 14,140 Euro dollars for patients over 30 years old in Sweden. If quality of life was taken into account, patients receiving prophylactic treatment had higher mean utilities than patients on on-demand therapy. The incremental effectiveness ratios in Germany were 1.2 million Euro dollars per quality-adjusted life year gained for patients 30 years or younger and HIV-positive and 2.2 million Euro dollars for patients 30 years or younger and HIV-negative. In the group aged over 30 years and HIV-positive the on-demand treatment strategy was dominant, whereas in the over 30 years/HIV-negative group the incremental cost-utility ratio was 4.7 million Euro dollars per quality-adjusted life year. Based on our decision analysis, the use of prophylactic treatment was overall more effective than on-demand therapy in young haemophiliacs, but at extremely high cost.
Assuntos
Custos de Cuidados de Saúde/estatística & dados numéricos , Hemofilia A/tratamento farmacológico , Hemofilia A/economia , Hemofilia B/tratamento farmacológico , Hemofilia B/economia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Estudos de Coortes , Análise Custo-Benefício , Europa (Continente) , Fator VIII/economia , Fator VIII/uso terapêutico , Feminino , Infecções por HIV/complicações , Pesquisas sobre Atenção à Saúde , Hemofilia A/virologia , Hemofilia B/virologia , Hepatite B/complicações , Hepatite C/complicações , Humanos , Masculino , Pessoa de Meia-Idade , Qualidade de Vida , Análise de RegressãoRESUMO
Haemophilia B is an inherited bleeding disorder associated with a deficiency of coagulation factor IX. The hallmark of the severe phenotype is recurrent and spontaneous bleeding into joints, which can lead to joint deformity and arthritis at an early age. Recombinant factor IX is now increasingly regarded as the treatment of choice because it does not transmit human pathogens. All patients in the UK now receive this product exclusively. Conventional treatment now consists of the administration of recombinant factor IX concentrate on a prophylactic basis to prevent bleeds and, hence, minimise disability in the long term. Trials of gene therapy are also underway, but these are in the very early stages and will not be a realistic option for at least another 20 years.